Genetic Disorder L.P.Kkr Ge... Net Worth

The estimated Net Worth of Genetic Disorder L.P.Kkr Ge... is at least $1.16 Billion dollars as of 17 February 2021. Genetic Ge owns over 3,450,000 units of BridgeBio Pharma Inc stock worth over $869,396,578 and over the last 4 years Genetic sold BBIO stock worth over $288,413,249.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Genetic Ge BBIO stock SEC Form 4 insiders trading

Genetic has made over 2 trades of the BridgeBio Pharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Genetic sold 3,450,000 units of BBIO stock worth $208,621,500 on 17 February 2021.

The largest trade Genetic's ever made was selling 3,450,000 units of BridgeBio Pharma Inc stock on 17 February 2021 worth over $208,621,500. On average, Genetic trades about 2,919,845 units every 133 days since 2020. As of 17 February 2021 Genetic still owns at least 31,060,971 units of BridgeBio Pharma Inc stock.

You can see the complete history of Genetic Ge stock trades at the bottom of the page.

Insiders trading at BridgeBio Pharma Inc

Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo, and Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.

What does BridgeBio Pharma Inc do?

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.

Complete history of Genetic Ge stock trades at BridgeBio Pharma Inc

BridgeBio Pharma Inc executives and stock owners

BridgeBio Pharma Inc executives and other stock owners filed with the SEC include:

• Neil Kumar,
  Chief Executive Officer, Director
• Charles Homcy,
  Chairman of Pharmaceuticals, Lead Director
• Uma Sinha,
  Chief Scientific Officer
• Brian Stephenson,
  Chief Financial Officer
• Eric Aguiar,
  Independent Director
• Ali Satvat,
  Independent Director
• Jennifer Cook,
  Independent Director
• Dr. Neil Kumar Ph.D.,
  Co-Founder, CEO & Director
• Dr. Brian C. Stephenson C.F.A., Ph.D.,
  CFO, Sec. & Principal Accounting Officer
• James Momtazee,
  Independent Director
• Richard Scheller,
  Chairman of Research and Development, Director
• Dr. Michael Thomas Henderson M.D.,
  Chief Bus. Officer
• Dr. Charles J. Homcy M.D.,
  Chairman of Pharmaceuticals & Lead Director
• Dr. Richard H. Scheller Ph.D.,
  Chairman of R&D and Director
• Dr. Cameron Turtle DPHIL, Ph.D.,
  Chief Strategy Officer
• Randal Scott,
  Independent Director
• Brenton Saunders,
  Independent Director
• Andrew Lo,
  Independent Director
• Ronald Daniels,
  Independent Director
• Michael Henderson,
  Chief Business Officer
• Cameron Turtle,
  Senior Vice President - Portfolio Management and Corporate Development
• Frank Mccormick,
  Chairman of Oncology
• Dr. Frank McCormick Ph.D.,
  Chairman of Oncology
• Grace Rauh,
  VP of Communications
• Dr. Uma Sinha Ph.D.,
  Chief Scientific Officer
• Yi Ching Yau,
  Chief Accounting Officer
• Genetic Disorder L.P.Kkr Ge...,
  
• Management Holdings L.P.Kkr...,
  
• Douglas A. Dachille,
  
• Fred Hassan,
  
• Global Performance Llc Viki...,
  
• Global Investors Lp Viking ...,
  
• Genetic Disorder L.P.Robert...,
  
• Yi Ching Yau,
  Chief Accounting Officer
• Brian M. Stolz,
  Chief Operating Officer
• Hannah Valantine,
  
• Brent L Saunders,
  Director
• Andrea Ellis,
  
• Global Investors Lp Viking ...,
  
• Thomas Trimarchi,
  President and COO